Clinical Research Directory

Inclusion Criteria: * Female patients aged 18 or above * Ability to provide informed consent documentation indicating that they understand the purpose of and procedures required for the study, and are willing to participate in the study * Estrogen/Progesterone receptor +ve HER2 negative disease confirmed on prior biopsy (primary or metastatic site). * Metastatic breast cancer being staged or re-staged prior to treatment of metastatic disease (including those presenting with up-front metastatic disease with primary breast cancer in-situ and those who have progressed on a line of treatment for metastatic breast cancer that are suitable for another line of treatment) * Metastatic breast cancer being staged or restaged prior to change in treatment with standard imaging within 3 weeks of enrolment (CT CAP, bone scan, FDG PET CT) Exclusion Criteria: * Pregnancy or lactation (patients should use highly effective methods of contraception during and for 12h after administration) * Significant inter-current acute illness as per investigator discretion that prevent undertaking study procedures * History of current active malignancy as per investigator discretion other than breast cancer. * Known or expected hypersensitivity to 68Ga NeoB